Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AZD2171 With Paclitaxel/Carboplatin in Japanese Patients With Advanced or Metastatic NSCLC
jRCT2080220478Phase 2
- Sponsor
- AstraZeneca
- Start
- Dec 2007
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of cediranib in non-small cell lung cancer (NSCLC) (3 arms), sponsored by AstraZeneca.
02
Drugs
cediranib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on jRCT2080220478.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080220478.